4 completed, 3 terminated, 1 withdrawn. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow IDX 899: new trials by email Literature Review of IDX 899 trials Research Report on IDX 899
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects. GSK1349572, GSK2248761 - Infection, Human Immunodeficiency Virus I | Phase 1 | Withdrawn | ViiV Healthcare | 2011-03-01 | 2014-12-24 | |
| Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET) GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Efavirenz 600 mg once daily - Infection, Human Immunodeficiency Virus | Phase 2 | Terminated | ViiV Healthcare | 23 | 2010-11-18 | 2017-11-17 |
| Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine - Infection, Human Immunodeficiency Virus | Phase 2 | Terminated | ViiV Healthcare | 30 | 2010-10-05 | 2017-11-17 |
| A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects. YASMIN, GSK2248761, Placebo - Infection, Human Immunodeficiency Virus, HIV Infections | Phase 1 | Terminated | ViiV Healthcare | 13 | 2010-09-14 | 2019-02-20 |
| A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects. GSK2248761, Simvastatin, Atorvastatin - Infection, Human Immunodeficiency Virus | Phase 1 | Completed | GlaxoSmithKline | 14 | 2010-06-01 | 2010-11-05 |
| A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects Raltegravir, GSK2248761, GSK2248761 + Raltegravir - Infection, Human Immunodeficiency Virus | Phase 1 | Completed | ViiV Healthcare | 15 | 2010-04-01 | 2017-09-11 |
| Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults. GSK2248761, Lopinavir/ritonavir, HAART - Infection, Human Immunodeficiency Virus | Phase 2 | Completed | ViiV Healthcare | 8 | 2009-10-20 | 2018-11-29 |
| Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs darunavir/ritonavir, lopinavir/ritonavir, Midazolam - Healthy Subjects, Infection, Human Immunodeficiency Virus | Phase 1 | Completed | GlaxoSmithKline | 24 | 2009-06-01 | 2010-11-03 |
Infections (8) · Acquired Immunodeficiency Syndrome (7) · HIV Infections (4) · Immunologic Deficiency Syndromes (1) · Retroviridae Infections (1) · Sexually Transmitted Diseases (1)
ViiV Healthcare (6) · GlaxoSmithKline (2)
United States (6) · Argentina (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Romania (1) · Spain (1)